WHAT PEOPLE WITH AMYOTROPHIC LATERAL SCLEROSIS

(ALS) SHOULD KNOW ABOUT NASAL VENTILATION

 

By Pamela A. Cazzolli, R.N.

 

Amyotrophic lateral sclerosis (ALS) is a degenerative disease of the motor nerves, occurring mostly in adults. Ultimately, this results in progressive respiratory muscle weakness, causing progressive inability to move air in and out of the lungs. This eventually leads to breathing failure, unless respiratory weakness is effectively treated with mechanical ventilation to maintain breathing. In fact, when respiratory failure is prevented and treated, and other treatable complications are avoided, ALS itself is not fatal. Until the 1990s, people with ALS used tracheostomy positive pressure ventilation (TPPV), usually as a result of emergency hospitalization, without advance decision making. A tracheostomy is a surgical opening made in the neck; ventilation is provided through a tube inserted in the windpipe, the trachea. Tracheostomy ventilation is “invasive” life support, and through this alternative, people with ALS may choose to prevent respiratory failure; this may allow life to continue as long as five to ten or more years in some cases. In the past decade, however, nasal positive pressure ventilation (NPPV) has become the treatment of choice for ALS and often an alternative to tracheostomy. Nasal ventilation can be used successfully to treat respiratory symptoms, as well as to prevent and treat respiratory failure in ALS, thus increasing survival in selected individuals. Use of nasal ventilation also provides experience and time for people with ALS to decide whether to have a tracheostomy, if nasal ventilation fails.

 

Nasal ventilation is a noninvasive treatment in which a portable ventilator delivers positive pressure air through the nose, into the lungs; inflating the lungs. The ventilator uses air from the room and delivers the air to the lungs, through a long plastic tubing attached to a nasal interface. A nasal interface is either a small silicone mask fitted around the nose, or “nasal pillows” that are cushioned inserts that fit comfortably inside the nostrils. The nasal interface is anchored to the nose by wearing special straps or headgear. Some people can use a mouthpiece (straight, angled, or one with a lip seal) in the daytime if their lip muscles can hold on to the mouthpiece without air escaping from the mouth, or by using straps. Rotating from one interface to another can help promote comfort and to avoid pressure to the same areas of skin.

 

People who have trouble keeping their mouth closed may need to use a chin-strap to close the mouth. Full face masks are also available to alleviate problems due to air leaks from the mouth or congested nasal passages. These are not used frequently because they impair the ability to talk, as well as increase the risk of aspirating oral secretions.

 

The best candidates for nasal ventilation are people who are “nonbulbar” (those who can talk and swallow and do not have excessive oral secretions). In fact, people are nonbulbar are sometimes able to successfully use nasal ventilation for up to 24 hours a day, unless bulbar symptoms become advanced. Studies have shown that some nonbulbar ALS patients who have used nasal ventilation have prolonged their survival for as long as six years, until bulbar impairment became severe. Thus, nonbulbar users of NPPV tend to live longer than those who are bulbar, unless tracheostomy is used. Factors for successful NPPV use include: the absence of excessive oral secretions, effective airway clearance, properly fitting nasal or oral interfaces, willingness to wear interfaces, the desire to live, and good caregiver support.

 

Initiating nasal ventilation at the appropriate time is essential in order to treat early symptoms, prevent respiratory failure, avoid emergency decision making, and prevent unwanted tracheostomy. Nasal ventilation should be initiated when significant respiratory decline is detected. Symptoms of respiratory impairment vary widely; and may include: shortness of breath, the inability to take a deep breath, a weak cough force, discomfort in breathing in any position except sitting or standing upright and a low voice volume. Some people experience headaches, particularly in the morning, daytime drowsiness or restlessness. Because signs of respiratory muscle weakness may be overlooked, careful and accurate monitoring of the respiratory status is necessary. People with ALS should have periodic pulmonary function tests (PFTs) and an evaluation by a pulmonary physician. This will help assess the degree of respiratory muscle involvement, the progression of symptoms, early recognition of reversible complications, and pending respiratory failure. Then a good decision can be made as to when nasal ventilation should be started. One of the simple tests that indicates significant respiratory impairment is a vital capacity (VC) of 50% or less. People with ALS should know the results of their pulmonary tests and what they mean. This will allow ALS individuals and their families to participate collaboratively in decision making with their doctors.

 

Noninvasive nasal or mouthpiece ventilation can be provided with either a volume cycled or a bi-level ventilator. The volume ventilator delivers a preset volume of air for each breath cycle. The bi-level ventilator delivers two preset levels of pressure: one level of air pressure is for inhalation, called the “IPAP” (inspiratory positive airway pressure) and the other for exhalation, called the “EPAP” (expiratory positive airway pressure). To achieve and maintain adequate ventilation and relief of respiratory symptoms, appropriate ventilator settings are essential. The IPAP setting should be set high enough to

 

adequately inflate the lungs, while the EPAP should be low, since the higher the EPAP, the more difficult it may be to exhale. To maintain ventilation, people with ALS who use a bi-level ventilator should use one that includes a Spontaneous / Timed (S/T) mode. The Spontaneous mode assists the breath, each time you start to breathe in. While the Timed mode provides regular assisted breaths that do not require your own effort, breaths are provided if you are unable to do so.

 

People with ALS should not use CPAP (continuous positive airway pressure) machines because this increases the work of breathing out. CPAP is used to treat obstructive sleep apnea, rather than for neuromuscular disorders where “assisted ventilation” is needed.4 Also, oxygen should not usually be used as a substitute for positive pressure ventilation. Use of oxygen alone can result in respiratory failure when assisted ventilation is needed to treat respiratory muscle weakness. Sometimes oxygen will be needed in addition to assisted ventilation if a person has pneumonia or a lung disease.

 

Nasal ventilation is usually initially used when sleeping at night and during naps during the day. The amount of hours necessary to relieve symptoms and to maintain optimal ventilation depends on each person’s changing respiratory status. Thus, NPPV is not needed “only” when sleeping. The progression of respiratory muscle weakness will gradually increase the need to use NPPV if maintaining ventilation is desired.

 

Although the physician must prescribe the type of ventilator and the settings, the respiratory therapist should work in conjunction with the physician and patient to help evaluate and identify optimal settings. The ventilator settings should be adjusted for the patient’s comfort and relief of symptoms. Only the patient can determine what is most comfortable. Patients who are not comfortable will not use their ventilator. Initiation of nasal ventilation requires sufficient time to adapt to the new equipment and to make adjustments for the desired outcome. Therefore, it is often ideal for the respiratory care practitioner to initiate the treatment in the patient’s home. Careful follow-up visits are needed to be sure that the ventilator settings are adjusted as needed. A simple pulse oximeter reading should be done at each visit to be sure that oxygen saturation is 95% or greater, without supplemental oxygen.

 

Initially, noninvasive NPPV was developed using volume ventilators. The bi-level ventilator was first introduced in 1990 by Respironics, Inc. (Pittsburgh, PA) and their original model with the spontaneous / timed mode was called, the Respironics BiPAPâ S/T, meaning “Bi” for the two levels of pressure, and “PAP” for positive airway pressure. As the pioneer of bi-level ventilation, the Respironics “BiPAP” became widely used; no other bi-level machine became available until later. Thus, when bi-level ventilation became more prevalent, all the bi-level ventilators have been commonly referred to as the “BiPAP.” However, “bi-level ventilator” is the best general term. Although other brands are available, the BiPAP should only be used to refer to the Respironics bi-level ventilator. Other leading bi-level models include: the KnightStar 335 (Mallinkrodt Inc., Pleasanton, CA), the Sullivanâ VPAPâ II ST-A (ResMed Corp, Poway, CA) and the Quantum PSV (Respironics, Inc.).

 

The bi-level and volume ventilators have advantages and disadvantages. The bi-level ventilators are simple to use, lighter weight (ranging 7.7 to 19 pounds), and less expensive. They compensate for air leaks. Although they have no built-in battery, most are able to be adapted to run on an external battery that is kept charged. The volume cycled ventilators may be more complex to use, more expensive and weigh an average range of 28 to 35 pounds. However, they are more powerful, have more safety features, and have an internal battery that automatically works if there is a power failure. They are able to run a few hours without an external battery, but are designed to attach easily to an external battery. One of the latest ventilator models is the Pulmonetic Systems: LTV1000 (Colton, CA), a ventilator that is both a pressure support and volume cycled unit. It is the size of a laptop computer, weighs only 12.6 pounds, but is more expensive.

 

Whatever ventilator is used, people with ALS should have the right to indicate their ventilator preference, know their prescribed ventilator settings and what they mean. To assure on-going and safe use, ventilator users should only use a ventilator that has an external battery, as well as a cigarette lighter adapter to run on a vehicle battery. Patients and families should understand and be skilled in the use of their respiratory equipment. This includes knowing the ventilator settings and sometimes how to change settings if needed (such as the IPAP pressure if necessary within the parameters prescribed by the physician). Therefore, use of a ventilator with easy access to the controls (note: some bi-level devices are designed so the user has no access to the controls). The patient or family should report immediately if the delivery of air no longer feels sufficient or comfortable so their doctor, nurse and respiratory practitioner can quickly respond. You need a clear contingency plan, so you know what to do in case problems occur.

 

People with ALS, and their loved ones, have the right to accurate, sufficient and understandable information for planning and decision making. This will allow the best choices, and avoid making hasty decisions. It is wiser to plan well ahead than to be one minute too late. The objective is to achieve your goals, to achieve optimal life satisfaction.

 

REFERENCES:

 

  1. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996; 139 (Suppl.):123-128.

 

  1. Cazzolli PA, Oppenheimer EA. Use of nasal and tracheostomy positive pressure ventilation in patients with ALS: changing patterns and outcomes. Neurology 1998; 50:Suppl 4:A417-A418. abstract.

 

  1. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997; 127:450-453.

 

  1. Bach JR: Guide to the Evaluation and Management of Neuromuscular Diseases. Philadelphia, Hanley & Belfus, 1999.

 

Special thanks to Edward A. Oppenheimer, MD of Kaiser Permanente Medical Center, Los Angeles for the review of this article.

 

Revised: August 2000

Ó 2000. Pamela A. Cazzolli, R.N., Canton, Ohio USA. All Rights Reserved.

 

Reprinted with permission by Pamela A. Cazzolli, R.N., ALS Nurse Consultant in Canton, OH. During her practice, she has interacted with over 2000 people with ALS. For many years, she served as the Nurse Consultant of the ALS Association Eastern Ohio Chapter, including six years as the Nurse Coordinator of the ALS Center at the Cleveland Clinic Foundation. As a pioneer investigator of the use of nasal ventilation in ALS patients, she was one of the first to report that nasal ventilation prolongs survival in selected individuals with ALS.